Characteristics of airway inflammation and bronchodilator reversibility in COPD: A potential guide to treatment

Chest

Volumn 126, Issue 2, 2004, Pages 375-381

  Perng, Diahn Warng ^a,b   Huang, Han Yu ^b   Chen, Hua Ming ^b   Lee, Yu Chin ^b   Perng, Reury Perng ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

COPD; Eosinophils; Induced sputum; Neutrophils; Reversibility

Indexed keywords

ALBUMIN; AUTACOID; BETA 2 ADRENERGIC RECEPTOR; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; EOTAXIN; INTERLEUKIN 8; MUCOLYTIC AGENT; RANTES; THEOPHYLLINE;

AGED; AIRWAY; ARTICLE; BRONCHITIS; BRONCHODILATATION; CELL SECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH SURVEY; HUMAN; INFLAMMATORY CELL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; SPUTUM EXAMINATION; T LYMPHOCYTE;

EID: 4143146425     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.2.375     Document Type: Article

References (34)

1. National Institutes of Health, National Heart, Lung, and Blood Institute. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report. Bethesda, MD: National Heart, Lung, and Blood Institute, 2001
2. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033-1039
3. Fahy JV, Liu J, Wong H, et al. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993; 147:1126-1131
4. Linden M, Rasmussen JB, Piitulainen E, et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am Rev Respir Dis 1993; 148:1226-1232
5. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153:530-534
6. Ronchi MC, Piragino C, Rosi E, et al. Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. Thorax 1996; 51:1000-1004
7. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993; 92:537-548
8. Balzano G, Stefanelli F, Iorio C, et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease: relationship with neutrophils and airway function. Am J Respir Crit Care Med 1999; 160:1486-1492
9. Louis R, Lau LC, Bron AO, et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161:9-16
10. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-674
11. Boushey HA. Glucocorticoid therapy for chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1990-1991
12. Fujimoto K, Kubo K, Yamamoto H, et al. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest 1999; 115:697-702
13. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356:1480-1485
14. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:14-20
15. Postma DS, Sluiter HJ. Prognosis of chronic obstructive pulmonary disease: the Dutch experience. Am Rev Respir Dis 1989; 140:S100-S105
16. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:1773-1777
17. Dales RE, Spitzer WO, Tousignant P, et al. Clinical interpretation of airway response to a bronchodilator: epidemiologic considerations. Am Rev Respir Dis 1988; 138:317-320
18. Pin I, Radford S, Kolendowicz R, et al. Airway inflammation in symptomatic and asymptomatic children with methacholine hyperresponsiveness. Eur Respir J 1993; 6:1249-1256
19. Peleman RA, Rytila PH, Kips JC, et al. The cellular composition of induced sputum in chronic obstructive pulmonary disease. Eur Respir J 1999; 13:839-843
20. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165:1592-1596
21. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875-879
22. Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155:1529-1534
23. Ciba Foundation Guest Symposium. Terminology, definitions and classification of chronic pulmonary emphysema and related conditions. Thorax 1959; 14:286-299
24. Burge PS, Calverley PM, Jones PW, et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58:654-658
25. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
26. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948-1953
27. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909
28. Dippolito R, Foresi A, Chetta A, et al. Eosinophils in induced sputum from asymptomatic smokers with normal lung function. Respir Med 2001; 95:969-974
29. Pizzichini E, Pizzichini M, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998; 158:1511-1517
30. Nisar M, Earis JE, Pearson MG, et al. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146:555-559
31. Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease: Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med 1992; 327:1413-1419
32. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123:1441-1449
33. Sitkauskiene B, Sakalauskas R, Malakauskas K, et al. Reversibility to a beta2-agonist in COPD: relationship to atopy and neutrophil activation. Respir Med 2003; 97:591-598
34. Gross NJE, Skorodin MS. Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjects. Chest 1989; 96:984-987